Nossiter, Julie http://orcid.org/0000-0002-8597-7624
Morris, Melanie
Cowling, Thomas E.
Parry, Matthew G. http://orcid.org/0000-0002-9695-6052
Sujenthiran, Arunan
Aggarwal, Ajay
Payne, Heather
van der Meulen, Jan http://orcid.org/0000-0002-9451-2335
Clarke, Noel W.
Cathcart, Paul
Article History
Received: 22 March 2021
Revised: 9 August 2021
Accepted: 11 August 2021
First Online: 8 September 2021
Competing interests
: JN, MM, TEC, MGP, AS, AA, HP, JvM, NWC and PC are members of the Project Team of the National Prostate Cancer Audit (ExternalRef removed) which is commissioned by the Healthcare Quality Improvement Partnership (ExternalRef removed) as part of the National Clinical Audit and Patient Outcomes Programme, and funded by NHS England and the Welsh Government. Neither HQIP nor NHS England or the Welsh Government had any involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. The researchers had full independence from the Healthcare Quality Improvement Partnership. JvM reports a contract with the Healthcare Quality Improvement Partnership for the provision of the National Prostate Cancer Audit (ExternalRef removed) funded by the Healthcare Quality Improvement Partnership (ExternalRef removed). HP was supported by the University College London Hospitals/University College London Comprehensive Biomedical Research Centre. MGP was partly supported by the NHS National Institute for Health Research through an Academic Clinical Fellowship (ACF-2014-20-002). The views expressed in this article are those of the authors and not necessarily those of the NHS or the Department of Health and Social Care. NWC has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Bayer, Janssen, Sanofi Aventis, Takeda, Ipsen and Ferring.